• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

ThromboGenics to launch ocriplasmin in United States

Article

ThromboGenics NV has confirmed a date of Jan. 14 for the U.S. launch of ocriplasmin intravitreal injection (Jetrea).

 

Leuven, Belgium-ThromboGenics NV has confirmed a date of Jan. 14 for the U.S. launch of ocriplasmin intravitreal injection (Jetrea).

The product is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion (VMA). The U.S. price for a single-use glass vial is set at $3,950.

The product represents a paradigm shift and for the first time offers a pharmacological treatment option to patients suffering with symptomatic VMA. The FDA approved Jetrea in October 2012 as the first pharmacological agent for the treatment of symptomatic VMA.

ThromboGenics will be making a presentation concerning the launch on Wednesday, Jan. 9 during the 31st Annual J.P. Morgan Healthcare Conference in San Francisco.

 

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
Elizabeth Yeu, MD, highlights from a corneal case report for a patient undergoing the triple procedure
William F. Wiley, MD, shares some key takeaways from his ASCRS presentation on binocularity and aperture optics.
© 2024 MJH Life Sciences

All rights reserved.